Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373383 · ClinicalTrials.gov registry record · Phase 2
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
A Phase 2 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 2
- Development phase
- 411
- Enrollment target
NCT03373383 is a Phase 2 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 411 participants.
The verdict
NCT03373383, a Phase 2 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 411 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.
Interventions
- OTHER Placebo
- DRUG Padsevonil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2020-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373383
The ClinicalTrials.gov registry entry for NCT03373383 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03373383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03373383 about?
NCT03373383 is a clinical study titled "Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy". The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.
What is the current status of trial NCT03373383?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 411 participants. The study started on 2018-02-12. Estimated completion is 2020-01-30.
What interventions are being tested in trial NCT03373383?
The interventions under investigation include: Placebo (OTHER), Padsevonil (DRUG).
Who is sponsoring clinical trial NCT03373383?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.